Rice Bucket Challenge: Water-starved South Asia fills buckets with rice, not ice

Karachi, Jun 22: India-born renowned Pakistani Shia scholar and author Talib Jauhari passed away here after a prolonged illness. He was 80.

Jauhari, who was born on August 27, 1939 in Patna, is survived by his three sons, Dawn News reported on Monday.

He migrated to Pakistan along with his father in 1949, two years after the Partition.

After obtaining early education from his father, he went to Iraq where he studied religion for 10 years under the renowned Shia scholars of that time.

Jauhari, who was on a ventilator in the intensive care unit of a private hospital for the past 15 days, breathed his last on Sunday night.

His son Riaz Jauhari confirmed his death and said that the body has been shifted to Ancholi Imambargah for the funeral prayers, The Express Tribune newspaper quoted his son as saying.

Jauhari was respected among his sect as he was a class fellow of the widely revered scholar Ayatollah Sayyid Ali al-Husayni al-Sistani.

He was also a poet, historian and philosopher and authored many books.

Pakistan Prime Minister Imran Khan has condoled Jauhari's death.

Washington, Feb 23: U.S. president Donald Trump on Saturday said he was looking forward to being with his "great friends" in India next week as he retweeted a short video in which his face was superimposed on the hit movie-character Bahubali, showing the president as a great saviour bringing peace to his kingdom.

Trump will pay a state visit to India on February 24 and 25, accompanied by a high-level delegation including first lady Melania Trump, his daughter Ivanka, son-in-law Jared Kushner and a galaxy of top American officials.

"Look so forward to being with my great friends India!" Trump said in the tweet.

Along with the tweet, Trump retweeted an 81-second video by a Twitter account identified as "Sol" with the handle Solmemes1.

"To celebrate Trump's visit to India I wanted to make a video to show how in my warped mind it will go... USA and India united!" the handle Solmemes1 tweeted in the original post with the video.

Trump appears as a great saviour, in the short animated clip, riding on a chariot with Melania. A few stills later, Trump is seen riding a horse carrying on his shoulders his son Donald Jr and daughter Ivanka.

Later, he is welcomed by Narendra Modi in a village setting. Hundreds and thousands of people are seen welcoming Trump in the video.

"This week Trump will visit India and in celebration I have created a new meme for the occasion... You few, who are my patrons, get to see it first!" Sol told viewers on subscription content service Patreon on Saturday. A few hours later, Trump retweeted the video.

In the Twitter description, Sol describes herself as "award winning master memetician, professor of memology at University of GFY, my views are my own and not associated with real life."

The Trump-Bahubali video, which ends with "USA and India United", went viral after Trump retweeted it. In a few hours, it was seen by nearly 6 lakh people.

Sol in one of her previous posts, dated January 23, writes she was inspired by a video of Bahubali sent to her by a friend, which is the story of 'good defeating evil.'

This inspired Sol to create her first Bahubali-theme meme. The video, lasting 93 seconds, is titled "Jiyo Re Baahu Trump", in which the first lady is seen wearing a saree. "Jiyo Re Bahubali," is the theme song of the video.

"I just loved this video when I saw it! A friend sent it to me and he told me that it is the story of good defeating evil... it was so fitting I had to make it (meme)..." Sol wrote in her post.

Sol's posts show that she is an admirer of Trump. Sol's January 23 video was released at the peak of Trump's impeachment proceedings.

Trump is seen being greeted by an elephant, which bears the logo of the Republican Party.

Towards the end of the video, Trump is seen riding the elephant, and putting on fire the effigy of "Raavan" marked as "D" in a big circle representing the opposition Democratic Party.

An arrow is given by warrior Narendra Modi to the First Lady, who then passes it on to Trump, before he lights the effigy.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.